Newly developed nano-biocomposite embedded hydrogel to enhance drug loading and modulated release of anti-inflammatory drug
A newly developed iron-based nano-biocomposite (nano Fe-CNB) impregnated alginate formulation (CA) is proposed to improve drug loading and exhibit pH-responsive behavior of model anti-inflammatory drug-ibuprofen for controlled release applications. The proposed formulation is investigated with conventional β-CD addition in CA. The nano Fe-CNB-based formulations with and without β-CD, (Fe-CNB β-CD CA and Fe-CNB CA) are compared with only CA and β-CD incorporated CA formulations. The results indicate the incorporation of nano-biocomposite or β-CD into CA enhances the drug loading (>40%). However, pH-responsive controlled release behavior is observed for nano Fe-CNB based formulations only. The release studies from Fe-CNB β-CD CA indicate ∼ 45% release in stomach pH (1.2) within 2 h. In contrast, Fe-CNB CA shows ∼20% release only in stomach pH and improved release (∼49%) at colon pH (7.4). The rheology and swelling studies indicate Fe-CNB CA remains intact in stomach pH with a minimal drug release, but it disintegrates at colon pH due to charge reversal behavior of nano-biocomposite and ionization of polymeric chains. Thus, Fe-CNB CA formulation is found to be a potential candidate for targeting colon delivery, inflammatory bowel disease, and post-operative conditions.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Pharmaceutical development and technology - 28(2023), 3-4 vom: 01. März, Seite 299-308 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Varghese, Sophia [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-Inflammatory Agents |
|---|
| Anmerkungen: |
Date Completed 18.05.2023 Date Revised 18.05.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/10837450.2023.2193254 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM354456105 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM354456105 | ||
| 003 | DE-627 | ||
| 005 | 20231226062248.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/10837450.2023.2193254 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1181.xml |
| 035 | |a (DE-627)NLM354456105 | ||
| 035 | |a (NLM)36940227 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Varghese, Sophia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Newly developed nano-biocomposite embedded hydrogel to enhance drug loading and modulated release of anti-inflammatory drug |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.05.2023 | ||
| 500 | |a Date Revised 18.05.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a A newly developed iron-based nano-biocomposite (nano Fe-CNB) impregnated alginate formulation (CA) is proposed to improve drug loading and exhibit pH-responsive behavior of model anti-inflammatory drug-ibuprofen for controlled release applications. The proposed formulation is investigated with conventional β-CD addition in CA. The nano Fe-CNB-based formulations with and without β-CD, (Fe-CNB β-CD CA and Fe-CNB CA) are compared with only CA and β-CD incorporated CA formulations. The results indicate the incorporation of nano-biocomposite or β-CD into CA enhances the drug loading (>40%). However, pH-responsive controlled release behavior is observed for nano Fe-CNB based formulations only. The release studies from Fe-CNB β-CD CA indicate ∼ 45% release in stomach pH (1.2) within 2 h. In contrast, Fe-CNB CA shows ∼20% release only in stomach pH and improved release (∼49%) at colon pH (7.4). The rheology and swelling studies indicate Fe-CNB CA remains intact in stomach pH with a minimal drug release, but it disintegrates at colon pH due to charge reversal behavior of nano-biocomposite and ionization of polymeric chains. Thus, Fe-CNB CA formulation is found to be a potential candidate for targeting colon delivery, inflammatory bowel disease, and post-operative conditions | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a NSAID | |
| 650 | 4 | |a Nano-biocomposite | |
| 650 | 4 | |a controlled release | |
| 650 | 4 | |a cyclodextrin | |
| 650 | 4 | |a ibuprofen | |
| 650 | 4 | |a pH-responsive | |
| 650 | 4 | |a swelling | |
| 650 | 7 | |a Delayed-Action Preparations |2 NLM | |
| 650 | 7 | |a Hydrogels |2 NLM | |
| 650 | 7 | |a Anti-Inflammatory Agents |2 NLM | |
| 650 | 7 | |a Drug Carriers |2 NLM | |
| 700 | 1 | |a Chaudhary, Jai Prakash |e verfasserin |4 aut | |
| 700 | 1 | |a Thareja, Prachi |e verfasserin |4 aut | |
| 700 | 1 | |a Ghoroi, Chinmay |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmaceutical development and technology |d 1998 |g 28(2023), 3-4 vom: 01. März, Seite 299-308 |w (DE-627)NLM094740194 |x 1097-9867 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2023 |g number:3-4 |g day:01 |g month:03 |g pages:299-308 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/10837450.2023.2193254 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2023 |e 3-4 |b 01 |c 03 |h 299-308 | ||